$6 Spinrite Silk Bamboo Yarn, 2.2 oz, Blush Arts, Crafts Sewing Knitting Crochet Yarn Max 75% OFF Spinrite Silk Bamboo Yarn 2.2 Blush oz Spinrite,Blush,Silk,2.2,Arts, Crafts Sewing , Knitting Crochet , Yarn,Yarn,,/kainite61375.html,$6,oz,,Bamboo,oif.jp $6 Spinrite Silk Bamboo Yarn, 2.2 oz, Blush Arts, Crafts Sewing Knitting Crochet Yarn Spinrite,Blush,Silk,2.2,Arts, Crafts Sewing , Knitting Crochet , Yarn,Yarn,,/kainite61375.html,$6,oz,,Bamboo,oif.jp Max 75% OFF Spinrite Silk Bamboo Yarn 2.2 Blush oz

Max 75% Daily bargain sale OFF Spinrite Silk Bamboo Yarn 2.2 Blush oz

Spinrite Silk Bamboo Yarn, 2.2 oz, Blush

$6

Spinrite Silk Bamboo Yarn, 2.2 oz, Blush

|||

Product description

PATONS-Silk Bamboo Yarn. This yarn is a luxurious blend of silk and bamboo for a marvelous drape supple softness and an elegant sheen. The colors are vivid and on-trend. This yarn knits and crochets beautifully: stitched slide effortlessly. Weight category: 3 70% Bamboo/30% Silk 1.8oz/65g 102yds/93m.Gauge 22sts x 28r = 4in/10cm on size 6/4mm knitting needles and G6/4mm crochet hook. Care: hand wash dry flat do not bleach do not iron do not dry clean. Imported.


From the manufacturer

Spinrite Silk Bamboo Yarn, 2.2 oz, Blush

CURRENT ISSUE
November, 2021

No. 106 (11)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days
ARTICLES IN THREE SENTENCES
Article

Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma

Transducin β-like protein 1 (TBL1) plays a crucial role in controlling the stability of regulatory proteins involved in cell proliferation and autophagy induction. This study revealed that, unlike normal B cells, diffuse large B-cell lymphoma cells express abundant levels of TBL1 and its overexpression correlates with poor clinical outcome. Targeting TBL1 promoted lymphoma cell death in vitro and in vivo. These results provide the rationale for targeting TBL1 as a novel therapeutic strategy in diffuse large B-cell lymphoma.

Youssef Youssef et al.

Article

Targeting shear gradient activated von Willebrand factor by the novel single-chain antibody A1 reduces occlusive thrombus formation in vitro

The authors of this study developed a single-chain antibody that targets a shear gradient-specific conformation of von Willebrnad factor (VWF). In vitro studies showed that this antibody specifically reduces VWF-GPIbα binding and thrombus formation at sites of shear rate gradients but does not block platelet deposition and aggregation under constant shear rate. This characteristic places the antibody in a new class of antiplatelet therapy for selective blockade of pathological thrombus formation while maintaining normal hemostasis.

Thomas Hoefer et al.

Case Report

Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia

A 26-year-old female developed vaccine-induced immune thrombotic thrombocytopenia (VITT) with cerebral venous thrombosis and bi-hemispheric hemorrhage following the first dose of the ChAdOx1 nCoV-19 vaccine. The treatment protocol, based on intravenous immunoglobulins, dexamethasone and argatroban was successful with almost complete clinical, laboratory and radiological response. This experience supports the application of an early and multidisciplinary therapeutic approach in cases of VITT, with the possibility of avoiding deaths and obtain a resolution of the syndrome.

Sara Bonato et al.

Letter

Allogeneic hematopoietic stem cell transplantation from non-sibling 10/10 HLA-matched related donors: a single-center experience

This retrospective study compared the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in 23 patients with hematologic malignancies transplanted from non-sibling fully matched related donors to that of patients who underwent conventional haplo-HSCT. Subjects transplanted from fully matched related donors showed trends to a higher relapse rate and lower cumulative incidence of grade II-IV acute graft-versus-host disease, but overall survival was similar. The authors concluded that individualized adjustment of the immunosuppressive treatment is reasonable for this category of patients.

Yaoyao Shen et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA